ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Sodium thiosulfate: Drug information

Sodium thiosulfate: Drug information
(For additional information see "Sodium thiosulfate: Patient drug information" and see "Sodium thiosulfate: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Pedmark
Brand Names: Canada
  • Seacalphyx
Pharmacologic Category
  • Antidote;
  • Antidote, Extravasation
Dosing: Adult
Cyanide poisoning

Cyanide poisoning (alternative agent): Note: If hydroxocobalamin is unavailable, then sodium nitrite may be used in conjunction with sodium thiosulfate; administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (Ref). The benefit of sodium thiosulfate in combination with hydroxocobalamin has been questioned; however, cases of favorable outcomes following severe poisonings have been reported (Ref). Consider consultation with a clinical toxicologist or poison control center.

IV: 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return.

Calciphylaxis

Calciphylaxis (off-label use): Note: Optimal dose is not established.

Patients on dialysis: IV: 25 g administered 3 times per week during the last hour of or after the hemodialysis session. Continue therapy until there is complete resolution of symptoms (Ref).

Patients not on dialysis (normal renal function or mildly reduced GFR): IV: 25 g administered 3 times per week (Ref).

Extravasation management

Extravasation management (off-label use):

Mechlorethamine: SUBQ (off-label route): Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution (into the extravasation site) for each mg of mechlorethamine suspected to have extravasated (Ref).

Cisplatin, concentrated: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation, may repeat SUBQ injections several times over the next 3 to 4 hours (Ref).

Bendamustine: SUBQ: Bendamustine extravasation may be managed with 1/6 M (~4%) sodium thiosulfate solution in the same manner as mechlorethamine extravasation (Ref).

Management of delayed calcium extravasation

Management of delayed calcium extravasation (calcinosis cutis) (off-label use): Note: Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote (Ref).

IV: 12.5 g over 30 minutes, administered 3 times per week; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (Ref).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination is significant and risk of adverse effects may be increased in patients with renal impairment.

Calciphylaxis (off-label use): No dosage adjustment necessary. When used for patients not on dialysis (normal renal function or mildly reduced GFR), because sodium thiosulfate is cleared by the kidney, dose may be adjusted based on appearance of adverse effects (eg, metabolic acidosis, hypotension) (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Sodium thiosulfate: Pediatric drug information")

Note: Parenteral sodium thiosulfate is available as two separate products with unique indications, concentrations, and dosing which should not be interchanged.

Cisplatin-induced ototoxicity; risk reduction

Cisplatin-induced ototoxicity; risk reduction:

Note: Reserve use for patients receiving cisplatin infusions ≤6 hours duration; with cisplatin infusions >6 hours, irreversible ototoxicity may have already occurred and sodium thiosulfate may not reduce this risk. Prior to each sodium thiosulfate dose, administer antiemetic therapy and ensure that sodium level is within normal limits.

Infants, Children, and Adolescents:

Pedmark (125 mg/mL solution):

<5 kg: IV: 10 g/m2/dose 6 hours after completion of each cisplatin infusion. Note: If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in <10 hours, do not administer sodium thiosulfate. Refer to individual protocols (Ref).

5 to 10 kg: IV: 15 g/m2/dose 6 hours after completion of each cisplatin infusion. Note: If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in <10 hours, do not administer sodium thiosulfate. Refer to individual protocols (Ref).

>10 kg: IV: 20 g/m2/dose 6 hours after completion of each cisplatin infusion. Note: If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in <10 hours, do not administer sodium thiosulfate. Refer to individual protocols (Ref).

Cyanide poisoning

Cyanide poisoning:

Note: Hydroxocobalamin is the preferred cyanide antidote; if hydroxocobalamin is unavailable, sodium nitrite may be used in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (Ref). Dosing in pediatric patients is based on the 250 mg/mL (25%) solution and expressed in multiple units (mg/kg, mL/kg); use extra caution. Administer in conjunction with sodium nitrite. Consider consultation with a clinical toxicologist or poison control center.

Infants, Children, and Adolescents: 250 mg/mL solution (25%): IV: 250 to 412.5 mg/kg (1 to 1.65 mL/kg of a 25% solution); maximum dose: 12.5 g/dose (50 mL of a 25% solution) (Ref). Monitor patients for 24 to 48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.

Extravasation management

Extravasation management: Limited data available:

Mechlorethamine extravasation: Children and Adolescents: SUBQ: 1/6 M (~4%) solution: Inject 2 mL for each mg of mechlorethamine suspected to have extravasated; administer immediately into the extravasation site (Ref).

Cisplatin extravasation, concentrated: Infants, Children, and Adolescents: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation; may repeat SUBQ injections several times over the next 3 to 4 hours (Ref).

Dosing adjustment for toxicity:

Cisplatin-induced ototoxicity; risk reduction:

Infants, Children, and Adolescents: Sodium thiosulfate (125 mg/mL): Pedmark: IV:

Sodium Thiosulfate (Pedmark) Recommended Dosage Adjustments for Adverse Reactions

Adverse Reaction

Severity

Dosage Modification

Hypernatremia

>145 mmol/L

Withhold sodium thiosulfate (Pedmark) and administer supportive care as needed. When sodium is within normal limits, resume therapy at same dose.

Hypokalemia

Grade 3 or 4

Withhold sodium thiosulfate (Pedmark) and supplement potassium as needed. When potassium is within normal limits, resume therapy at same dose.

Hypersensitivity reaction

Grade 1 or 2

Immediately stop sodium thiosulfate (Pedmark) infusion and administer appropriate care. Administer antihistamines or glucocorticoids (if appropriate) prior to subsequent doses.

Grade 3 or 4

Immediately stop sodium thiosulfate (Pedmark) and administer appropriate care. Permanently discontinue sodium thiosulfate (Pedmark).

Other adverse reactions

Grade 3

Withhold sodium thiosulfate (Pedmark) until ≤ grade 1. Resume at the same dose.

Grade 4

Permanently discontinue sodium thiosulfate (Pedmark).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for infants, children, and adolescents administered sodium thiosulfate concomitantly with cisplatin, unless otherwise specified.

Frequency not defined:

Endocrine & metabolic: Hypermagnesemia, hypernatremia, hypokalemia, hyponatremia, hypophosphatemia

Gastrointestinal: Nausea, stomatitis, vomiting

Hematologic & oncologic: Decreased hemoglobin

Miscellaneous: Fever

Postmarketing (any population; sodium thiosulfate may be administered with either cisplatin or sodium nitrite):

Cardiovascular: Hypertension, hypotension

Endocrine & metabolic: Hypercalcemia (Shen 2019), hypocalcemia, metabolic acidosis (Sohal 2020)

Gastrointestinal: Salty taste

Hematologic & oncologic: Prolonged bleeding time, prolonged prothrombin time

Local: Localized warm feeling

Nervous system: Disorientation, headache

Contraindications

Pedmark: History of severe hypersensitivity to sodium thiosulfate or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Electrolyte abnormalities: Pedmark: Hypernatremia and hypokalemia may occur. Do not initiate treatment with baseline serum sodium >145 mmol/L; initiate appropriate treatment as necessary.

• GI effects: Pedmark: Nausea and vomiting may occur. Premedication with antiemetics may be administered; initiate additional antiemetics and supportive care as needed.

• Hypersensitivity: Pedmark: Hypersensitivity reactions has been reported. Immediately discontinue treatment and initiate appropriate care as needed if hypersensitivity occurs.

Special populations:

• Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In these patients, the induction of methemoglobinemia with amyl nitrite or sodium nitrite is contraindicated until carbon monoxide levels return to normal due to the risk of tissue hypoxia. Methemoglobinemia decreases the oxygen-carrying capacity of hemoglobin and the presence of carbon monoxide prevents hemoglobin from releasing oxygen to the tissues. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. However, hydroxocobalamin is the preferred cyanide antidote and should be considered to avoid the nitrite-related problems and because sodium thiosulfate has a slow onset of action.

• Sulfite hypersensitivity: May contain sodium sulfite; sulfite exposure may cause hypersensitivity reactions, including anaphylaxis and life-threatening or severe asthma episodes in susceptible patients. The presence of sulfite hypersensitivity should not preclude the use of this medication when being used for cyanide poisoning.

Dosage form considerations:

• Parenteral sodium thiosulfate is available as two separate products with unique indications, concentrations, and dosing which should not be interchanged.

Other warnings/precautions:

• Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain; however, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Signs of cyanide poisoning may include altered mental status, mydriasis, nausea/vomiting, dyspnea, chest tightness, hyper-/hypotension, plasma lactate ≥8 mmol/L. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Consider consultation with a clinical toxicologist or poison control center. Ototoxicity risk reduction: Safety and efficacy have not been established when administered following cisplatin infusions >6 hours; with cisplatin infusions >6 hours, irreversible ototoxicity may have already occurred and sodium thiosulfate may not reduce this risk.

• Initiation of treatment: Cyanide poisoning: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.

• Return of symptoms: Cyanide poisoning: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24 to 48 hours; repeat treatment (one-half the original dose) should be administered if symptoms return.

Warnings: Additional Pediatric Considerations

Electrolyte abnormalities (hypernatremia, hypokalemia) have been reported in pediatric ototoxicity risk reduction clinical trials. Hypernatremia developed in 12% to 26% of patients, including grade 3 in one patient. A sodium thiosulfate dose of 20 g/m2 contains 162 mmol/m2 of sodium, a 15 g/m2 dose contains 121 mmol/m2 of sodium, and 10 g/m2 contains 81 mmol/m2 of sodium. Do not administer sodium thiosulfate (Pedmark) in patients with serum sodium levels >145 mmol/L. Due to an underdeveloped sodium homeostasis system compared to older infants, use of sodium thiosulfate (Pedmark) is not recommended in neonatal patients. Hypokalemia was reported in 15% to 27% of patients. Patients should be monitored for signs of hypernatremia and hypokalemia and treated and supplemented as needed.

When used to reduce the risk of ototoxicity from cisplatin, there is an increased risk of nausea and vomiting in pediatric patients; antiemetics should be given prior to administration.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Pedmark: 12.5% (100 mL)

Generic: 25% [250 mg/mL] (50 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Pedmark Intravenous)

12.5% (per mL): $137.01

Solution (Sodium Thiosulfate Intravenous)

250 mg/mL (per mL): $2.32

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Seacalphyx: 25% [250 mg/mL] (100 mL) [contains disodium edta, sodium metabisulfite]

Generic: 25% [250 mg/mL] (10 mL, 50 mL)

Administration: Adult

IV: Cyanide poisoning: Administer by IV infusion over 10 to 30 minutes. Decrease rate of infusion in the event of significant hypotension. When used with sodium nitrite, administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (Ref). If sodium thiosulfate is used in combination with hydroxocobalamin, administer via different IV lines (Ref).

Calciphylaxis (off-label use): Administer by IV infusion over 30 to 60 minutes (Ref).

Extravasation management (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula (temporarily keep in place for cisplatin extravasation to allow for sodium thiosulfate administration through the needle/cannula); elevate extremity.

Mechlorethamine: Inject SUBQ (off-label route) into the extravasation site using ≤25-gauge needle; change needle with each injection (Ref).

Cisplatin, concentrated: Inject into the existing IV line; consider also injecting 1 mL as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation using a new 25- or 27-gauge needle for each injection (Ref).

Bendamustine: SUBQ: Bendamustine extravasation may be managed with sodium thiosulfate in the same manner as mechlorethamine extravasation (Ref).

Administration: Pediatric

Parenteral: Route of administration dependent upon use.

IV:

Cisplatin-induced ototoxicity: Pedmark (125 mg/mL): Note: Sodium thiosulfate (Pedmark) can cause nausea and vomiting; antiemetics should be administered prior to treatment. Premedication with antihistamines or glucocorticoids (if appropriate) should be administered to patients with a history of hypersensitivity reactions.

Administer undiluted by IV infusion over 15 minutes at 6 hours after end of cisplatin infusion. Note: If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in <10 hours, do not administer sodium thiosulfate.

Cyanide poisoning: Administer undiluted (25% solution) by IV infusion over 10 to 30 minutes immediately after the administration of sodium nitrite (Ref). Decrease rate of infusion in the event of significant hypotension.

Extravasation management: Cisplatin, concentrated: Inject 1/6 M (~4%) sodium thiosulfate solution into the existing IV line in addition to SUBQ injections around extravasation site (Ref).

SUBQ: Extravasation management: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula unless treating cisplatin extravasation (for cisplatin extravasation, temporarily keep needle/cannula in place to allow for IV sodium thiosulfate to be administered); elevate extremity.

Mechlorethamine: Inject SUBQ 1/6 M (~4%) sodium thiosulfate solution into the extravasation site using ≤25-gauge needle; change needle with each injection (Ref).

Cisplatin, concentrated: Inject SUBQ 1/6 M (~4%) sodium thiosulfate solution clockwise into the area around the extravasation site using a new 25- or 27-gauge needle for each injection (Ref).

Use: Labeled Indications

Cyanide poisoning (alternative agent): Treatment of acute, life-threatening cyanide poisoning in combination with sodium nitrite.

Note: The preferred antidote for the treatment of acute cyanide poisoning is hydroxocobalamin, especially in patients who have concurrent carbon monoxide poisoning (eg, smoke inhalation), significant anemia, or G6PD deficiency (Anseeuw 2013). Sodium nitrite and sodium thiosulfate should be considered only if hydroxocobalamin is unavailable, there is a contraindication to the use of hydroxocobalamin, or if the patient has a known sensitivity to hydroxocobalamin or vitamin B12 analogues. Sodium thiosulfate is not generally used as the sole intervention for cyanide toxicity as it has a delayed onset of action, small Vd, and short half-life. Consider consultation with a clinical toxicologist or poison control center.

Ototoxicity: To reduce the risk of ototoxicity associated with cisplatin in pediatric patients ≥1 month of age with localized, nonmetastatic solid tumors.

Limitations of use: Safety and efficacy have not been established when administered following cisplatin infusions longer than 6 hours.

Use: Off-Label: Adult

Calciphylaxis; Management of mechlorethamine extravasation; Management of delayed calcium extravasation (calcinosis cutis); Management of concentrated cisplatin (≥0.4 mg/mL) extravasation; Management of bendamustine extravasation

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Cyanide crosses the placenta; untreated cyanide poisoning can be fatal to the mother and fetus.

In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). However, other treatments may be preferred for the treatment of cyanide toxicity during pregnancy (Culnan 2018; Roderique 2012).

Breastfeeding Considerations

It is not known if sodium thiosulfate is present in breast milk.

Cyanide and thiocyanate (which forms after sodium thiosulfate combines with cyanide) are present in breast milk. Clinicians should be aware that the breastfed infant may have been exposed to cyanide and may also require treatment for cyanide poisoning (De Capitani 2017); consultation with a clinical toxicologist or poison control center is highly recommended. It is not known when breastfeeding may safely be restarted after administration of sodium thiosulfate for the treatment of cyanide poisoning.

Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.

Monitoring Parameters

Cyanide poisoning: Monitor for at least 24 to 48 hours after administration; BP and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO2 gradient; chloride and anion gap; serum methemoglobin and oxyhemoglobin.

Ototoxicity prevention: Serum potassium and sodium (baseline and as clinically indicated). Monitor for signs and symptoms of hypersensitivity, hypernatremia, and hypokalemia.

Extravasation management: Monitor and document extravasation site for pain, blister formation, skin sloughing, arm/hand swelling/stiffness; monitor for fever, chills, or worsening pain.

When used in the management of delayed calcium extravasation (calcinosis cutis), monitor for non-anion gap acidosis, hypocalcemia, severe nausea (Stefanos 2023).

Mechanism of Action

Cyanide toxicity: Serves as a sulfur donor in rhodanese-catalyzed formation of thiocyanate (much less toxic than cyanide).

Extravasation management: Neutralizes the reactive species of mechlorethamine; reduces the formation of hydroxyl radicals which cause tissue injury.

Cisplatin ototoxicity: Neutralizes cisplatin to produce an inactive platinum complex.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Vd:

Thiosulfate:

Pediatric patients ≥1 month of age: 0.23 L/kg.

Adults: 0.15 L/kg (Howland 2019).

Thiocyanate: 0.25 L/kg.

Half-life elimination:

Thiosulfate:

Pediatric patients ≥1 month of age: 20 to 50 minutes.

Adults: ~3 hours (Howland 2019).

Thiocyanate: 2.7 days; prolonged with renal impairment to ~9 days.

Excretion:

Pediatric patients ≥1 month of age: Urine (approximately 50% thiosulfate as unchanged drug, >95% within the first 4 hours after administration).

Adults: Urine (~20% to 50% thiosulfate as unchanged drug).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AT) Austria: Natriumthiosulfat;
  • (AU) Australia: Hospira sodium thiosulphate;
  • (CO) Colombia: Tiosulfato de sodio;
  • (DE) Germany: Natriumthiosulfat;
  • (EE) Estonia: Natriumthiosulfat;
  • (FR) France: Hyposulfene | Natriumthiosulfat;
  • (GR) Greece: Natriumthiosulfat/dr. franz kohler chemie;
  • (IE) Ireland: Pedmarqsi;
  • (IT) Italy: Sodio Tiosolf Sal | Sodio tiosolfato;
  • (JP) Japan: Detoxol;
  • (KR) Korea, Republic of: Ametox | Thiosulfate;
  • (LT) Lithuania: Natrium thiosulfas;
  • (LV) Latvia: Natrii thiosulfas | Natrium thiosulfas;
  • (NZ) New Zealand: Sodium thiosulphat;
  • (PL) Poland: Natrium thiosulfatum | Natriumthiosulfat;
  • (RU) Russian Federation: Natrium thiosulfas | Sodium thiosulphate;
  • (SG) Singapore: Sodium thiosulphate;
  • (TW) Taiwan: Detoxol
  1. Ackermann F, Levy A, Daugas E, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol. 2007;143(10):1336-1337. [PubMed 17938357]
  2. Anseeuw K, Delvau N, Burillo-Putze G, et al. Cyanide poisoning by fire smoke inhalation: a European expert consensus. Eur J Emerg Med. 2013;20(1):2-9. doi:10.1097/MEJ.0b013e328357170b [PubMed 22828651]
  3. Auriemma M, Carbone A, Di Liberato L, . Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature. Am J Clin Dermatol. 2011;12(5):339-346. [PubMed 21834598]
  4. Agency for Toxic Substances and Disease Registry (ATSDR), “Medical Management Guidelines for Hydrogen Cyanide (HCN).” Available at http://www.atsdr.cdc.gov/MHMI/mmg8.pdf
  5. Albanell J and Baselga J, "Systemic Therapy Emergencies," Semin Oncol, 2000, 27(3):347-61. [PubMed 10864222]
  6. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol. 2007;143(2):269-270. [PubMed 17310015]
  7. Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140. doi:10.1002/bdra.10007 [PubMed 12769509]
  8. Bebarta VS, Pitotti RL, Borys DJ, et al, “Seven Years of Cyanide Ingestions in the USA: Critically Ill Patients are Common, but Antidote Use is Not,” Emerg Med J, 2011, 28(2):155-8. [PubMed 20511644]
  9. Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376-2385. doi:10.1056/NEJMoa1801109 [PubMed 29924955]
  10. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43(6):1104-1108. [PubMed 15168392]
  11. Culnan DM, Craft-Coffman B, Bitz GH, et al. Carbon monoxide and cyanide poisoning in the burned pregnant patient: an indication for hyperbaric oxygen therapy. Ann Plast Surg. 2018;80(3)(suppl 2):S106-S112. doi:10.1097/SAP.0000000000001351 [PubMed 29461288]
  12. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021 [PubMed 28669553]
  13. De Capitani EM, Borrasca-Fernandes CF, Branco Pimenta M, et al. Suicide attempt with acetonitrile ingestion in a nursing mother. Clin Toxicol (Phila). 2017;55(8):929-933. doi:10.1080/15563650.2017.1324977 [PubMed 28494173]
  14. Dorr RT, "Antidotes to Vesicant Chemotherapy Extravasations," Blood Rev, 1990, 4(1):41-60. [PubMed 2182147]
  15. Ener RA, Meglathery SB, and Styler M, "Extravasation of Systemic Hemato-oncological Therapies," Ann Oncol, 2004, 15(6):858-62. [PubMed 15151940]
  16. Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. Lancet Child Adolesc Health. 2020;4(2):141-150. doi:10.1016/S2352-4642(19)30336-0 [PubMed 31866182]
  17. Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63-74. doi:10.1016/S1470-2045(16)30625-8 [PubMed 27914822]
  18. Gracia R and Shepherd G, "Cyanide Poisoning and Its Treatment," Pharmacotherapy, 2004, 24(10):1358-65. [PubMed 15628833]
  19. Hackett BC, McAleer MA, Sheehan G, Powell FC, O'Donnell BF. Calciphylaxis in a patient with normal renal function: response to treatment with sodium thiosulfate. Clin Exp Dermatol. 2009;34(1):39-42. [PubMed 18627391]
  20. Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann Emerg Med. 2007;49(6):806-813. doi:10.1016/j.annemergmed.2006.09.021 [PubMed 17098327]
  21. Hall AH, Rumack BH. Hydroxycobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med. 1987;5(2):115-121. doi:10.1016/0736-4679(87)90074-6 [PubMed 3295013]
  22. Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. In: Nelson LS, Howland, MA, Lewin NA, et al, eds. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw-Hill Education; 2019.
  23. Howland MA. Antidotes in depth: nitrites (amyl and sodium) and sodium thiosulfate. In: Nelson LS, Howland, MA, Lewin NA, et al, eds. Goldfrank's Toxicologic Emergencies. 11th ed. McGraw-Hill Education; 2019.
  24. Mao M, Lee S, Kashani K, Albright R, Qian Q. Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. J Med Toxicol. 2013;9(3):274-277. doi:10.1007/s13181-013-0305-z [PubMed 23636659]
  25. Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. Pediatr Emerg Care. 2013;29(11):1234-1240. [PubMed 24196100]
  26. Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” Chest, 2003, 123(3):897-922. [PubMed 12628894]
  27. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8(7):1162-1170. [PubMed 23520041]
  28. Pedmark (sodium thiosulfate) [prescribing information]. Hoboken, NJ: Fennec Pharmaceuticals Inc; September 2022.
  29. Peng T, Zhuo L, Wang Y, et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton). 2018;23(7):669-675. doi:10.1111/nep.13081 [PubMed 28603903]
  30. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, "Management of Chemotherapy Extravasation: ESMO--EONS Clinical Practice Guidelines," Eur J Oncol Nurs, 2012, 16(5):528-34. [PubMed 23304728]
  31. Polovich M, Whitford JN and Olsen M, Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.
  32. Reade MC, Davies SR, Morley PT, et al, “Review Article: Management of Cyanide Poisoning,” Emerg Med Australas, 2012, 24(3):225-38. [PubMed 22672162]
  33. Refer to manufacturer's labeling.
  34. Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. [PubMed 24420913]
  35. Roderique EJ, Gebre-Giorgis AA, Stewart DH, Feldman MJ, Pozez AL. Smoke inhalation injury in a pregnant patient: a literature review of the evidence and current best practices in the setting of a classic case. J Burn Care Res. 2012;33(5):624-633. doi:10.1097/BCR.0b013e31824799d2 [PubMed 22293595]
  36. Schulmeister L, "Extravasation Management: Clinical Update," Semin Oncol Nurs, 2011, 27(1):82-90. [PubMed 21255716]
  37. Shen C, Zhou Y, Chen Z, Rao L. Hypercalcemia associated with sodium thiosulfate treatment in a patient with calciphylaxis. Pol Arch Intern Med. 2019;129(9):638-640. doi:10.20452/pamw.14837 [PubMed 31111826]
  38. Sodium thiosulfate [prescribing information]. Scottsdale, AZ: Hope Pharmaceuticals; June 2020.
  39. Sohal R, George T. Sodium-thiosulfate induced life-threatening metabolic acidosis limiting treatment of calciphylaxis. Am J Case Rep. 2020;21:e919926. doi:10.12659/AJCR.919926 [PubMed 32336746]
  40. Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. Pharmacotherapy. 2023;43(4):321-337. doi:10.1002/phar.2794 [PubMed 36938775]
  41. Subramaniam K, Wallace H, Sinniah R, Saker B. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. Australas J Dermatol. 2008;49(1):30-34. [PubMed 18186845]
  42. Thompson JP and Marrs TC, “Hydroxocobalamin in Cyanide Poisoning,” Clin Toxicol, 2012, 50(10):875-85. [PubMed 23163594]
  43. Zakharov S, Vaneckova M, Seidl Z, et al. Successful use of hydroxocobalamin and sodium thiosulfate in acute cyanide poisoning: a case report with follow-up. Basic Clin Pharmacol Toxicol. 2015;117(3):209-212. doi:10.1111/bcpt.12387 [PubMed 25645744]
  44. Zitt E, König M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28(5):1232–1240. [PubMed 23291368]
Topic 9939 Version 154.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟